Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 1 - 10 of 34 results.

You searched for : July 2019 to July 2020.

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for ...

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062 Download the PDF version of Article July 27, 2020 ...

Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and ...

Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan Download the PDF version of Article July 22, 2020 Multi-year, multi-study...

Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer

Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer Download the PDF version of Article July 01, 2020 Phase 1 study now evaluating DS-1062, a TROP2...

ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastati ...

ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial Download the PDF version of Article...

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung ...

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial Download the PDF version of Article...

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung ...

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial Download the PDF version of Article...

ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorect ...

ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial Download the PDF version of Article May 29, 2020 Tokyo,...

Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KE ...

Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer Download the PDF version of...

Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC ...

Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline Download the PDF version of Article May 28, 2020 Coalition Ignites Strategic...

Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastati ...

Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer Download the PDF version of Article May 25, 2020 ENHERTU is the second innovative...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...